News

New research presented at ARVO 2023 suggests intravitreal brolucizumab led to the resolution of IRF and SRF in a significant number of patients with nAMD previously unresponsive to anti-VEGF therapy.

In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.

The research letter explains Native American ancestry was associated with a lower risk of asthma while African-American populations had an increased risk of asthma.

A California pilot program shows trained dogs may be able to sniff out COVID-19 with 90% specificity.

Among pediatric gastroenterologists surveyed, most were comfortable prescribing an infliximab biosimilar to patients who were tumor necrosis factor (TNF)-naïve and switching to a biosimilar for those in clinical remission.

This study evaluated tranexamic acid injection for post-acne vulgaris erythema, though its smaller sample size may require the findings to be reproduced in large-scale studies.

At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.

Phase 3 results presented at ARVO 2023 suggest a switch from aflibercept to SB15 led to no treatment-emergent issues such as loss of efficacy, increased adverse events, or increased immunogenicity.

Data from the BRAVES trial indicates 70% of patients undergoing metabolic or bariatric surgery with histologically confirmed NASH achieved resolution at 52 weeks.

There were significant positive associations found of overweight, obesity, and a 5-unit increase in BMI with colorectal cancer risk when using BMI measured 8-10 years prior to diagnosis.

Kim Zuber, PA-C, and Jane Davis, DNP, offer insight into the use of DOACs in people with atrial fibrillation and chronic kidney disease.

An analysis of the STATUS program suggests the percentage of patients that received an annual eye exam increased from 65.2% to 72.8% in the clinics utilizing the IDx-DR system.

An analysis of the AlzEye study presented at ARVO 2023 suggests a deep-learning model showed promise in predicting three-year incident MACE using OCT.

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.

National data show mortality rates climbed 23% in 2020, primarily driven by increases among American Indian or Alaska Native people.

Dupilumab shows significant reduction in annualized asthma exacerbation rate and improvement in lung function and asthma control in children with type 2 asthma, especially those with evidence of allergic asthma.

Patients in long-remission also presented with fecal bacterial composition that was similar to what was found in the healthy control group and there was a positive correlation between Akkermansia muciniphila abundance and time in remission.

On April 19, 2023, an expert clinical decision pathway and scientific statement were published simultaneously in JACC. Both of these documents were aimed at providing an overview of heart failure with preserved ejection fraction, including diagnosis and management, based on contemporary evidence.

On April 21, 2023, Medtronic announced the long-awaited US approval of their MiniMed 780G System with Smart Guard Technology and the Guardian 4 Sensor, which has been available in Europe for nearly 3 years.

Greater improvement in mild cognitive impairment for older adults with positive beliefs about age suggests a link between cognitive health and cultural or societal influences.

An analysis of 118 infant eyes in India suggests the biosimilar is safe and effective in treating ROP, with about one-third of eyes requiring reinjection at 7 weeks after the first dose.

In patients hospitalized with acute coronary syndrome and metabolic syndrome, obstructive sleep apnea was associated with an increased risk of major adverse cardiovascular and cerebrovascular events in women, but not in men.

An analysis of an ethnically diverse cohort in London found African Caribbean people experienced a 39% greater risk of sight-threatening DR, independent of traditional risk factors.

New research highlights the shared and unique characteristics of sleep and rest-activity rhythm measures among patients with schizophrenia.

The FDA requests no additional safety or efficacy data, the extension will provide time for the agency to review updates to the proposed Risk Evaluation and Mitigation Strategies (REMS) included in the application.

There was an increase in depression in the cystic fibrosis group, as well as an increase in anxiety in cystic fibrosis caregivers during the pandemic.

An analysis of hospitals in the Get With The Guidelines-HF program provides an overview of quality of care for patients treated at hospitals with a high proportion of Black patients relative to other hospitals within the program.

New research showed mixed results with perturbation-based balance training, or PBT, for older adults living in communities and their rate of falls.